ROBOSENSE
RoboSense LiDAR, the leading Smart LiDAR Sensor provider announced the second-generation intelligent solid-state LiDAR RS-LiDAR-M1 (referred to as "M1") completed mass production and delivery to the designated project for the first time. Since the start of production (SOP) to vehicle manufacturer in June 2021, more than ten batches of deliveries have been completed. This is the first mass production of solid-state LiDAR in the world, and also marks the advent of “an era of mass production for LiDAR”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210820005135/en/
Since July 2020, M1 has successively obtained designated cooperation orders for a number of mass-produced models around the world, including GAC Aion designated projects which official announced on last month . This mass production delivery for the designated automotive enterprises.
As the world's leading Smart LiDAR Sensor provider, RoboSense has completed iterations of five major and dozens of smaller versions on the smart solid-state LiDAR project in the past five years. Not only was it the first to implement the SOP version globally, but after the SOP was launched in Q2 2021, it leads the industry and achieved the first mass production delivery of the second-generation smart solid-state LiDAR.
M1 has smart software and hardware features under its small size appearance. In terms of smart hardware, M1 is based on the revolutionary two-dimensional MEMS smart chip scanning architecture, and has a unique "GAZE" function, which can adjust the scanning method according to the driving scene, improve the LiDAR perception ability, help enhance the automatic driving performance. In terms of smart software, M1 can be equipped with mature and embeddable point cloud AI perception algorithms.
At the same time, M1 guarantees the safety and reliability of point cloud data quality in various driving scenarios through a series of patented technologies, eliminates thorny problems in the industry from the product side, and built-in complete supporting functions such as OTA upgrade, stain detection, smart cleaning, smart heating, performance detection, power management, network management, etc. It has achieved SIL-2 and ASIL-B functional safety levels to help the vehicle perception system achieve ASIL-D functional safety design.
RoboSense will provide clients with continuously upgraded smart LiDAR system product solutions, jointly advance the evolution of smart driving experience, and accelerate the transformation and innovation of smart vehicle ecology. Promoting automated driving and advanced assisted driving passenger vehicles, commercial vehicles, logistics vehicles, robots, public smart transportation, and vehicle-road collaboration to achieve large-scale commercial use steadily and quickly.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom